Johnson and Johnson
Pharmaceutical Giants J&J and Bayer Announce Layoffs of Nearly 300 Employees in New Jersey
Johnson & Johnson, Bayer, layoffs, New Jersey, pharmaceutical industry, job cuts
Johnson & Johnson Boosts Talc Settlement by $1.1 Billion Amid Ongoing Negotiations
Johnson & Johnson, Talc Settlement, $1.1 Billion Increase, Cancer Lawsuits, Bankruptcy Plan
Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS
Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments
Johnson & Johnson Raises 2024 Guidance Following Acquisition of Shockwave Medical
Johnson & Johnson, Shockwave Medical, 2024 Guidance, Acquisition, Billion-Dollar Potential
Johnson & Johnson to Appeal $150 Million Verdict in HIV Meds Off-Label Marketing Case
Johnson & Johnson, HIV Meds, Off-Label Marketing, Appeal, $150 Million Verdict
Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years
Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry
Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial
Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment
Johnson & Johnson Expands Dermatology Portfolio with $850M Acquisition of Proteologix
Johnson & Johnson, J&J, Proteologix, atopic dermatitis, bispecifics, pipeline, acquisition, $850M
Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition
Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.
Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer
Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.